Pharmaceuticals Australia

Australia Dry Eye Disease Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia Dry Eye Disease Treatment Market Industry Trends and Forecast to 2034: Segmented by (Product, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $76.6 Mn Placeholder estimate
Estimate 2025 $83.1 Mn 1.1% of the global market
Projected 2034 $173.2 Mn 108.4% Adds $90.1 Mn over 9 forecast years
CAGR 2025–2034 8.5% Faster than 38% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.12% of the global market.
  • In APAC, the largest is China at $706.3 Mn.
  • Fastest growing: India at 10.1% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$90.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Dry Eye Disease Treatment Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $76.6 Mn — —
2025 (base) $83.1 Mn +$6.5 Mn —
2026 (forecast) $90.2 Mn +$7.1 Mn +8.5%
2027 (forecast) $97.8 Mn +$7.7 Mn +17.7%
2028 (forecast) $106.2 Mn +$8.3 Mn +27.7%
2029 (forecast) $115.2 Mn +$9.0 Mn +38.6%
2030 (forecast) $125.0 Mn +$9.8 Mn +50.4%
2031 (forecast) $135.6 Mn +$10.6 Mn +63.1%
2032 (forecast) $147.1 Mn +$11.5 Mn +77%
2033 (forecast) $159.6 Mn +$12.5 Mn +92.1%
2034 (forecast) $173.2 Mn +$13.6 Mn +108.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Dry Eye Disease Treatment Market Analysis at a glance
Market size, 2025$83.1 Mn placeholder estimate
Forecast, 2034$173.2 Mn placeholder estimate
Growth (CAGR), 2025–20348.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledDry Eye Syndrome Treatment
SegmentsProduct, channel and end user (see all)
Key playersAbbVie Inc., Novartis AG, Bausch and Lomb, Santen Pharmaceutical Co Ltd, Johnson & Johnson (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials15 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Dry Eye Disease Treatment Market Analysis Executive Summary

Dry eye disease treatments relieve gritty, sore and dry eyes using drops, prescription medicines and in-office devices.

Key segments of the dry Eye Disease Treatment market include product (Artificial Tears, Anti-Inflammatory Drugs and Punctal Plugs) and channel (Prescription and Over-the-Counter).

Bar chart: Australia Dry Eye Disease Treatment market size, 2024–2034, placeholder estimates. $76.6 Mn in 2024, $83.1 Mn in 2025 and $173.2 Mn in 2034, 8.5% CAGR.
Australia Dry Eye Disease Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Dry Eye Disease Treatment Market Dynamics

Market Growth Drivers

An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the dry Eye Disease Treatment market.

Opportunity

Longer-acting treatments, home-based care and screening in emerging markets give the dry Eye Disease Treatment market room to grow.

Market Restraints

High costs of new treatments, specialist shortages, low awareness and limited reimbursement in some countries hold back the dry Eye Disease Treatment market.

Competitive Landscape for Dry Eye Disease Treatment Market in Australia

The dry Eye Disease Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Dry Eye Disease Treatment Market in Australia

Dry Eye Disease Treatment in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 15 studies on Dry Eye Disease Treatment that are recruiting, active or about to start in Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for dry Eye Disease Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Dry Eye Disease Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Dry Eye Disease Treatment in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 4th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Inside Australia

Quick answers

Frequently asked questions

How big is the Dry Eye Disease Treatment market in Australia?
Placeholder estimate: about $83.1 Mn in 2025, rising to about $173.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Dry Eye Disease Treatment market in Australia growing?
Placeholder estimate: about 8.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Dry Eye Disease Treatment market report cover?
The report splits the market by product (Artificial Tears, Anti-Inflammatory Drugs, Punctal Plugs, Thermal Pulsation Devices), channel (Prescription, Over-the-Counter) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Dry Eye Disease Treatment market?
Key players include AbbVie Inc., Novartis AG, Bausch and Lomb, Santen Pharmaceutical Co Ltd and Johnson & Johnson.
What is driving the Dry Eye Disease Treatment market?
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the dry Eye Disease Treatment market.
Who regulates Dry Eye Disease Treatment in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Dry Eye Disease Treatment are running in Australia?
15 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Dry Eye Disease Treatment?
PubMed lists 34 papers on Dry Eye Disease Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on eye health

See the topic